Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Susan Young Rojahn

A View from Susan Young Rojahn

Medical Society Approval for Non-Invasive Prenatal Testing

Cell-free fetal DNA test can be primary screen for aneuoploidy-risk pregnancies, says Ob-Gyn society

  • November 21, 2012

Prenatal testing based on fetal DNA floating in a mother’s bloodstream got a nod from a professional medical society this week, which could benefit companies selling the diagnostic tools.

The American College of Obstetricians and Gynecologists recommended that non-invasive tests for abnormal numbers of chromosomes, called aneuploidies, be part of prenatal testing for at-risk pregnancies, which includes cases where the mother is over 35 or has a history of aneuploidy problems.

The committee’s opinion is “a reflection of the pent up interest and demand that’s out there,” says Jonathan Sheena, chief technology officer of Natera, a prenatal DNA diagnostics company in San Carlos, California. Other methods for detecting chromosomal aneuploidies, such as chorionic villus sampling or amniocentesis, carry a risk of miscarriage.  “We are very encouraged that ACOG is recognizing the demand and the promise of non-invasive prenatal testing and how it is going to improve care for pregnant mothers,” says Sheena.

While DNA diagnostics and other genomic tools are expected to move into many areas of medicine in coming years, they seems to be making inroads into reproductive medicine particularly quickly.  Medical researchers can examine fetal DNA from just a sample of a pregnant woman’s blood (see “New Tests Could Divine a Baby’s Genome Before Birth”) and some groups are even looking to predict baby genomes based on parental DNA (see “Genetic Screening Can Uncover Risky Matches at the Sperm Bank”). Even sequencing-machine manufacturers are jumping in (see “DNA Sequencing Leader Buys into Prenatal Testing”).

Natera is developing a non-invasive prenatal test for detecting aneuploidies of five chromosomes. Most other tests look for aneuploidies of just three chromosomes, the most famous being an extra chromosome 21, which causes Down Syndrome. But Natera’s sequencing-based test also looks for abnormal amounts of the X and Y chromosomes and results presented at this months’ American society for Human Genetics conference suggest the company’s test is highly accurate and sensitive across all five chromosomes.

The ACOG’s decision could be good news for Natera and other firms in the non-invasive prenatal testing space. As reported by GenomeWeb:

“[T]he recommendation should carry weight with payors, many of which we believe are considering national coverage decisions that could be swayed by these types of society recommendations or opinions,” William Blair analyst Brian Weinstein wrote in a note this morning.

Tech Obsessive?
Become an Insider to get the story behind the story — and before anyone else.

Subscribe today

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe and become an Insider.
  • Insider Plus {! insider.prices.plus !}* Best Value

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

    Bimonthly digital/PDF edition

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special interest publications

    Discount to MIT Technology Review events

    Special discounts to select partner offerings

    Ad-free web experience

  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning print magazine, unlimited online access plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

  • Insider Online Only {! insider.prices.online !}*

    {! insider.display.menuOptionsLabel !}

    Unlimited online access including articles and video, plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.